In a thought-provoking discussion, evolutionary biologist Bret Weinstein sheds light on a critical issue within scientific research: the use of genetically identical lab mice. This practice, as Weinstein argues, introduces significant biases, leading to unreliable results and potentially hindering the development of effective treatments and cures for various diseases. This problem, often overlooked, is pivotal for both the scientific community and the general public.
Weinstein, during his graduate studies in evolutionary biology, was captivated by the evolutionary trade-offs outlined by George Williams in his seminal work on senescence—the process by which organisms age. Williams’ theory of antagonistic pleiotropy posits that certain genes beneficial in early life can have detrimental effects in later life. This concept intrigued Weinstein, particularly in its application to the understanding of aging and disease.
Weinstein's curiosity led him to investigate telomeres—repetitive DNA sequences at the ends of chromosomes that shorten with each cell division. Two research groups, one focusing on aging and the other on cancer, were studying telomeres but not communicating with each other. One group believed that lengthening telomeres could combat aging, while the other thought shortening them could prevent cancer. Weinstein connected these seemingly contradictory findings through the lens of antagonistic pleiotropy, proposing that while telomeres protect against cancer in youth, their shortening leads to aging in later life.
A significant obstacle to Weinstein's hypothesis was the established fact that lab mice, known for their long telomeres, had short lifespans. If telomere length dictated aging, these mice should age slowly. However, Weinstein discovered that all lab mice were sourced from the same facility, Jackson Laboratory, and speculated that their long telomeres were an artifact of laboratory breeding rather than a natural trait.
Weinstein reached out to Carol Greider, a prominent scientist in the field, to test his hypothesis. Greider’s team found that wild mice, unlike lab mice, had short telomeres, confirming Weinstein’s suspicion. This finding not only supported his hypothesis about aging and cancer but also exposed a critical flaw in biomedical research: lab mice were poor models for human physiology due to their artificially elongated telomeres.
This discovery has profound implications for drug testing. Lab mice are used to test drug safety by assuming that short-lived animals will show long-term effects of drugs quickly. However, mice with elongated telomeres can replace their tissues indefinitely, potentially skewing toxicity results. Drugs deemed safe in these mice might be harmful to humans, as evidenced by the Vioxx scandal. Vioxx, a drug for arthritis, caused heart attacks and strokes in humans but appeared safe in lab mice, likely due to their unique telomere biology.
Despite publishing his findings, Weinstein faced resistance from the scientific community. The reluctance to acknowledge flaws in the standard research model highlights a systemic issue. The Vioxx case, where the drug caused severe cardiovascular issues yet showed paradoxically beneficial effects in lab mice, underscores the need for reevaluating our reliance on these animals for safety testing.
The problem with America's lab mice is not just a scientific curiosity but a matter of public health. The use of genetically identical mice with artificially elongated telomeres introduces biases that can lead to unsafe drugs reaching the market. To improve the accuracy of biomedical research and ensure the development of effective treatments, it is crucial to adopt more diverse and representative models. Weinstein’s work serves as a critical reminder of the need for vigilance and innovation in scientific research practices.
Source:
The Issue with the Peer-Review System
The FDA mice are broken
The problem with America’s Lab Mice and why it should matter to you - Bret Weinstein
